Reasons to Hold Avanos Medical Stock in Your Portfolio Now

Core Viewpoint - Avanos Medical, Inc. is positioned for growth due to its strong product line and focus on research and development, despite facing macroeconomic challenges and foreign exchange volatility [1][12][13] Company Performance - For the year-to-date period, Avanos' stock has decreased by 29.8%, while the industry rose by 3.5% and the S&P 500 grew by 12.1% [1] - The company reported a market capitalization of $744.5 million and an earnings yield of 10.7$170.4 million, but organic sales increased by 1.1% despite unfavorable foreign currency translation effects [14] - The Pain Management and Recovery segment saw normalized organic sales rise approximately 1%, with growth in ambIT partially offsetting supplier constraints affecting On-Q growth [6] Research and Development Focus - Avanos is committed to R&D, with expenses increasing by 18% year over year to $7.2 million in Q3 2024, aiming to enhance product efficiency and security [9] Future Outlook - The Zacks Consensus Estimate for Avanos' earnings in 2025 has improved by nearly 3$1.73 per share, with first-quarter 2025 revenue estimates at $173.5 million, indicating a 4.5% year-over-year improvement [15]